Abstract: The present invention relates to cell-derived vesicles with increased cellular uptake capacity and a method for producing same. The cell-derived vesicles of the present invention are produced by migrating cells to micropores, and exhibit the characteristic of expressing a protein marker that is different from that of exosomes naturally secreted by cells. The cell-derived vesicles with increased cellular uptake capacity, according to the present invention, have remarkably superior cellular uptake capacity as compared to natural exosomes secreted by cells, and thus can be effectively used to deliver various active substances, such as drugs and marker substances, into target cells.

Abstract: The present invention relates to a method for manufacturing cell-derived vesicles using a depth filter. The present invention has the effect of enabling cell-derived vesicles to be manufactured stably, economically, and in large quantities through a simplified process.

Abstract: Provided are a cell-extruding device including a membrane module, and a cell-extruding method using the same, wherein a suspension including cells is efficiently dispersed in the membrane module, thus preventing membrane clogging and increasing the usable area of the membrane, and thereby replacing the membrane and carrying out the process are easy, and production efficiency is increased.

Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

Abstract: Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.

Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.